πŸ‡ΊπŸ‡Έ FDA
Patent

US 10335365

Bladder cancer specific ligand peptides

granted A61KA61K38/00A61K47/51

Quick answer

US patent 10335365 (Bladder cancer specific ligand peptides) held by The United States of America as represented by the Department of Veteran Affairs (Washington DC) expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Department of Veteran Affairs (Washington DC)
Grant date
Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
40
CPC classes
A61K, A61K38/00, A61K47/51, A61K47/64, A61K47/66